肝细胞癌——如何确定治疗方案
Hepatocellular Carcinoma-How to Determine Therapeutic Options.
作者信息
Mehta Neil
机构信息
Division of Gastroenterology Department of Medicine University of California San Francisco San Francisco CA.
出版信息
Hepatol Commun. 2020 Jan 22;4(3):342-354. doi: 10.1002/hep4.1481. eCollection 2020 Mar.
Abstract
Deciding on specific treatment strategies involves not only tumor stage, performance status, and severity of underlying liver disease, but additional factors such as biomarkers, organ availability, and radiographic tumor response to treatment. In this review, we present hepatocellular carcinoma (HCC) cases to highlight how to determine therapeutic options for HCC in specific scenarios, including resection versus liver transplant, choice of initial local regional treatment, tumor downstaging, and systemic therapies for advanced HCC.
摘要
确定具体的治疗策略不仅涉及肿瘤分期、身体状况和潜在肝脏疾病的严重程度，还涉及其他因素，如生物标志物、器官可用性以及肿瘤对治疗的影像学反应。在本综述中，我们展示肝细胞癌（HCC）病例，以突出在特定情况下如何确定HCC的治疗方案，包括手术切除与肝移植、初始局部区域治疗的选择、肿瘤降期以及晚期HCC的全身治疗。
相似文献
1
Hepatocellular Carcinoma-How to Determine Therapeutic Options.肝细胞癌——如何确定治疗方案
Hepatol Commun. 2020 Jan 22;4(3):342-354. doi: 10.1002/hep4.1481. eCollection 2020 Mar.
2
Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.接受经导管肝动脉化疗栓塞术桥接或降期治疗的肝细胞癌的长期结局。
World J Gastroenterol. 2019 Oct 7;25(37):5687-5701. doi: 10.3748/wjg.v25.i37.5687.
3
Multicenter Study of Staging and Therapeutic Predictors of Hepatocellular Carcinoma Recurrence Following Transplantation.多中心研究：肝移植后肝细胞癌复发的分期和治疗预测因子。
Liver Transpl. 2018 Sep;24(9):1233-1242. doi: 10.1002/lt.25194.
4
Medical Management of Hepatocellular Carcinoma.肝细胞癌的医学管理
J Oncol Pract. 2017 Jun;13(6):356-364. doi: 10.1200/JOP.2017.022996.
5
Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma.米兰标准以外的肝移植或降期肝移植治疗肝细胞癌。
Expert Rev Gastroenterol Hepatol. 2018 Mar;12(3):265-275. doi: 10.1080/17474124.2018.1417035. Epub 2017 Dec 28.
6
Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.对超出米兰标准的肝细胞癌患者进行降期治疗：使用载药微球化疗栓塞的策略
J Vasc Interv Radiol. 2013 Nov;24(11):1613-22. doi: 10.1016/j.jvir.2013.07.024. Epub 2013 Sep 20.
7
Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices.肝细胞癌与肝移植：不断变化的模式与实践
Curr Treat Options Gastroenterol. 2017 Jun;15(2):296-304. doi: 10.1007/s11938-017-0133-3.
8
Reappraisal of Failures in Downstaging Treatment of Hepatocellular Carcinoma Prior to Liver Transplant-Preliminary Report on the Impact of Underestimations of Tumor Numbers and Tumor Sizes as Measured From Imaging Before Transplant.肝移植前肝细胞癌降期治疗失败的重新评估——关于移植前影像学测量低估肿瘤数量和肿瘤大小影响的初步报告
Transplant Proc. 2019 Jun;51(5):1428-1434. doi: 10.1016/j.transproceed.2019.03.020. Epub 2019 May 9.
9
Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma.高危复发性肝细胞癌的预防性肝移植
World J Hepatol. 2016 Nov 8;8(31):1309-1317. doi: 10.4254/wjh.v8.i31.1309.
10
Recent advances in the treatment of hepatocellular carcinoma.肝细胞癌治疗的最新进展。
Curr Opin Gastroenterol. 2013 May;29(3):285-92. doi: 10.1097/MOG.0b013e32835ff1cf.
引用本文的文献
1
Therapeutic targeting at genome mutations of liver cancer by the insertion of HSV1 thymidine kinase through Cas9-mediated editing.通过 Cas9 介导的编辑将 HSV1 胸苷激酶插入基因组突变的肝癌的治疗靶向。
Hepatol Commun. 2024 Mar 18;8(4). doi: 10.1097/HC9.0000000000000412. eCollection 2024 Apr 1.
2
Construction of a Novel Cuproptosis-Related ceRNA Network-SNHG3/miR-1306-5p/PDHA1 and Identification of SNHG3 as a Prognostic Biomarker in Hepatocellular Carcinoma.新型铜死亡相关ceRNA网络-SNHG3/miR-1306-5p/PDHA1的构建及SNHG3作为肝细胞癌预后生物标志物的鉴定
ACS Omega. 2023 Oct 3;8(41):38690-38703. doi: 10.1021/acsomega.3c06018. eCollection 2023 Oct 17.
3
The role of KPNA2 as a monotonically changing differentially expressed gene in the diagnosis, risk stratification, and chemotherapy sensitivity of chronic hepatitis B-liver cirrhosis-hepatocellular carcinoma.KPNA2作为慢性乙型肝炎-肝硬化-肝细胞癌诊断、风险分层及化疗敏感性中呈单调变化的差异表达基因的作用
J Cancer Res Clin Oncol. 2023 Nov;149(15):13753-13771. doi: 10.1007/s00432-023-05213-z. Epub 2023 Aug 1.
4
Cuproptosis regulator-mediated patterns associated with immune infiltration features and construction of cuproptosis-related signatures to guide immunotherapy.铜死亡调控因子相关模式与免疫浸润特征相关，并构建铜死亡相关特征以指导免疫治疗。
Front Immunol. 2022 Sep 29;13:945516. doi: 10.3389/fimmu.2022.945516. eCollection 2022.
5
Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort study.LI-RADS 2018 初始治疗反应在预测 TACE 后肝细胞癌患者生存中的表现：一项回顾性、单中心队列研究。
J Cancer Res Clin Oncol. 2021 Dec;147(12):3673-3683. doi: 10.1007/s00432-021-03603-9. Epub 2021 Mar 28.
6
Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy.右门静脉离断术联合乐伐替尼治疗后晚期肝细胞癌的转化性肝切除术
Surg Case Rep. 2020 Dec 10;6(1):318. doi: 10.1186/s40792-020-01078-3.
本文引用的文献
1
The impact of portal vein tumor thrombus on long-term survival after liver resection for primary hepatic malignancy.门静脉癌栓对原发性肝癌肝切除术后长期生存的影响。
HPB (Oxford). 2020 Jul;22(7):1025-1033. doi: 10.1016/j.hpb.2019.10.2439. Epub 2019 Nov 13.
2
Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.经导管动脉化疗栓塞联合射频消融治疗巴塞罗那临床肝癌分期 A 或 B 期肝细胞癌患者的临床结局改善，无论肿瘤大小：单中心回顾性病例对照研究结果。
BMC Cancer. 2019 Oct 22;19(1):983. doi: 10.1186/s12885-019-6237-5.
3
Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions.局部区域治疗肝细胞癌：当前证据和未来方向。
World J Gastroenterol. 2019 Aug 28;25(32):4614-4628. doi: 10.3748/wjg.v25.i32.4614.
4
Chemoembolization Combined with Radiofrequency Ablation for Medium-Sized Hepatocellular Carcinoma: A Propensity-Score Analysis.经导管化疗栓塞联合射频消融治疗中等大小肝细胞癌的疗效分析：倾向评分匹配研究。
J Vasc Interv Radiol. 2019 Oct;30(10):1533-1543. doi: 10.1016/j.jvir.2019.06.006. Epub 2019 Aug 27.
5
Percutaneous thermal ablation combined with simultaneous transarterial chemoembolization for hepatocellular carcinoma ≤5 cm.经皮热消融联合同步经动脉化疗栓塞治疗直径≤5 cm的肝细胞癌
J Cancer Res Ther. 2019;15(4):766-772. doi: 10.4103/jcrt.JCRT_250_19.
6
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.联合选择性内部放射治疗和索拉非尼对晚期肝细胞癌患者生存的影响。
J Hepatol. 2019 Dec;71(6):1164-1174. doi: 10.1016/j.jhep.2019.08.006. Epub 2019 Aug 14.
7
Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma.医疗机构对于直接作用抗病毒药物治疗肝细胞癌患者的态度和实践模式。
Clin Gastroenterol Hepatol. 2020 Apr;18(4):974-983. doi: 10.1016/j.cgh.2019.07.042. Epub 2019 Jul 26.
8
National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.国家在肝移植前对肝细胞癌降期的经验：肿瘤负担、甲胎蛋白和等待时间的影响。
Hepatology. 2020 Mar;71(3):943-954. doi: 10.1002/hep.30879. Epub 2019 Oct 15.
9
What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma?肝细胞癌的最佳肝移植标准是什么？
Clin Liver Dis (Hoboken). 2019 Feb 21;13(1):20-25. doi: 10.1002/cld.793. eCollection 2019 Jan.
10
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.直接作用抗病毒治疗慢性丙型肝炎和肝细胞癌患者的持续病毒学应答：系统评价和荟萃分析。
J Hepatol. 2019 Sep;71(3):473-485. doi: 10.1016/j.jhep.2019.04.017. Epub 2019 May 13.
Zotero 插件